Angina Pectoris, Chronic Coronary Syndrome, Hypertension
Conditions
Keywords
Coronary artery disease, Hypertension, Angina pectoris
Brief summary
Evaluation of the clinical outcomes of Benidipine initiated by physician's preference in patients with hypertension and/or angina pectoris (chronic coronary syndrome) presenting to cardiology outpatient clinics in Turkey.
Detailed description
* Benidipine is a dihydropyridine calcium channel blocker used in the treatment of hypertension and angina pectoris. There are currently no large-scale observational studies in these patient groups in Turkey. * There is no record of benidipine in clinicaltrials.gov, which is an important database especially for the registration of drug and interventional studies. * Therefore, it will be extremely important to include this study in clinicaltrials.gov and to evaluate the clinical efficacy of Bendipine in patients with hypertensive and/or angina pectoris in 7 geographical regions of Turkey.
Interventions
DRUGBenidipine Hydrochloride
The safety and efficacy of a dihydropyridine calcium channel blocker for the treatment of high blood pressure and/or angina pectoris
Sponsors
The Society of Prevention and Awareness of Cardiovascular Diseases
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Patients with hypertension and/or angina pectoris on the background of chronic coronary syndrome who have been receiving Benidipine treatment for at least 1 month and will continue to receive Benidipine treatment * Male or female outpatients, 18-80 years of age * Patients with mild to moderate essential hypertension who have been receiving or will continue Benidipine treatment for at least 1 month * Outpatients with clinically stable angina pectoris and patients who have been receiving or will continue Benidipine treatment for at least 1 month * Those who signed the written informed consent form
Exclusion criteria
* Patients with secondary hypertension * Emergency hypertensive patients * Having to take other medications during the study that may affect blood pressure * Allergic to DHP calcium antagonists * Evidence of decompensated congestive heart failure, unstable angina or severe arrhythmia * Severe renal or hepatic dysfunction * Pregnant or lactating women * Participation in other clinical trials within 3 months prior to this study * Patients who did not sign the consent form of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85 | 3 months |
| Change in angina symptom severity as measured by the Seattle Angina Questionnaire score from baseline to the end of study | 3 months |
Countries
Turkey (Türkiye)
Outcome results
None listed